不同制剂紫杉醇联合表柔比星治疗晚期乳腺癌的临床观察

目的 探讨紫杉醇或白蛋白结合型紫杉醇联合表柔比星治疗晚期乳腺癌的临床疗效及不良反应.方法 选取62例晚期乳腺癌患者,按照随机对照双盲的原则将其分为治疗组和对照组各31例,其中治疗组采用白蛋白结合型紫杉醇(260 mg/m2)联合表柔比星(75 mg/m2)治疗,对照组采用紫杉醇(175 mg/m2)联合表柔比星(75mg/m2)治疗.治疗2个周期后,观察比较两组患者的临床疗效及不良反应发生情况.结果 治疗组的治疗总有效率93.5％(29/31)高于对照组的71.0％(22/31),差异具有统计学意义(x2=5.420,P=0.020).两组不良反应发生率比较差异无统计学意义(P＞0.05).结论 与紫杉醇联合多柔比星比较,白蛋白结合型紫杉醇联合表柔比星治疗晚期乳腺癌疗效好且不良反应可耐受.

Efficacy of different formulations of paclitaxel combined with pirarubicin in treatment of advanced breast cancer

Objective To investigate the clinical efficacy and toxicity of paclitaxel or albumin-bound paclitaxel combined with pirarubicin in treatment of advanced breast cancer.Methods Sixty-two patients with advanced breast cancer were assigned to study group and control group with 31 cases in each group.Patients in study group received albumin-bound paclitaxel(260 mg/m2) combined with pirarubicin(75 mg/m2),and those in control group received paclitaxel(175 mg/ m2) combined with pirarubicin(75 mg/m2).The clinical efficacy and adverse reactions of the two groups were observed and compared after 2 cycles of chemotherapy.Results The total effective rate of study group was 93.5％ (29/31),which was significantly higher than that of control group (71.0％,22/31;x2 =5.42,P =0.020).No statistically significant difference was observed in the occurrence of adverse reactions between two groups (P ＞ 0.05).Conclusion Albumin-bound paclitaxel has a better clinical effect than paclitaxel when combined with pirarubicin in treating advanced breast cancer,and the adverse reactions are tolerable in both protocols.